Compare Li Auto Inc (LI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Li Auto Inc trades at $12.5 (market cap $12.28B), while State Street SPDR S&P Biotech ETF trades at $159.1. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | XBI | |
|---|---|---|
Market Cap | $12.28B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $26.69 | $164.28 |
52-Week Low | $11.74 | $86.92 |
Enterprise Value | $1.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.505, down 2.61% on the day, with a bearish technical signal and mixed earnings performance. Recent quarterly results show misses on EPS estimates, while revenue declined to $112.31 billion in 2025. The company maintains strong delivery growth, with 30,468 vehicles delivered in July 2026, but faces intense competition in China's EV market. Cash flow trends indicate operational challenges, with negative net cash flow of $9.00 billion in 2025.
Outlook remains cautious due to profitability pressures and competitive headwinds, though analyst consensus suggests moderate upside to a $14.80 price target. Key risks include execution on new model launches and macroeconomic volatility in the EV sector. The stock's current valuation metrics, such as a P/S of 0.83, may appeal to value-oriented investors if operational improvements materialize.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
